All studies
RecruitingPHASE3INTERVENTIONAL

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

This research is testing a new medicine called LOU064 for teenagers aged 12 to 17 who suffer from chronic hives (Chronic Spontaneous Urticaria, or CSU). These are hives that appear often and haven't fully cleared up with standard allergy medications. The study aims to see if LOU064 can effectively reduce hives and itching, how safe it is to use, and how the body handles the medicine. Participants will first receive either the new medicine or a dummy treatment, and then many will have the option to continue receiving the medicine for a longer period. There will also be a follow-up period to check on participants' health after the medicine is stopped.

At a glance

Status
Recruiting
Phase
PHASE3
Sponsor
Novartis Pharmaceuticals
Enrolment target
100
Start
11 Jul 2023
Estimated completion
30 Mar 2032

What is this study about?

This study is designed to explore a new potential treatment, called LOU064, for teenagers between 12 and 17 years old who experience chronic hives. These are hives that appear without a clear cause and have lasted for at least six months, even after trying common allergy medications. The main goal is to find out if LOU064 is better than a dummy treatment (placebo) at reducing the itching and hives, and how well the body tolerates it.

Participants will begin in a 'core period' where they receive either LOU064 or a placebo for about 24 weeks. After this, many will have the option to enter an 'open-label extension' where everyone receives LOU064, provided the doctors think it's suitable. This longer period helps researchers understand the long-term effects of the medicine. There's also a final follow-up period to monitor health after treatment has finished.

The findings from this study are very important. They will help doctors understand if LOU064 could become a new, effective, and safe treatment option for young people struggling with chronic hives that haven't responded to existing medicines. This could significantly improve the quality of life for many teenagers, helping them manage their symptoms better.

Key takeaways

  • This study is for teens (12-17) with persistent chronic hives.
  • It tests a new medicine, LOU064, against a dummy pill (placebo).
  • Participation involves regular visits and health checks over several months to years.
  • The goal is to see if LOU064 is safe and effective for long-term use.
  • You might receive the active medicine or a placebo in the first phase.
  • You can stop participating at any time.

Who may be eligible?

To join this study, you must be a male or female teenager aged between 12 and 17. You need to have had chronic hives (urticaria) for at least six months, and these hives shouldn't have improved enough even though you've been taking standard allergy pills (H1-antihistamines) as advised by your doctor. You also need to have experienced hives and itching frequently in the weeks leading up to the study, and these symptoms will be measured during the screening process.

There are also reasons why you wouldn't be able to join. For example, if you've already taken this specific experimental medicine or similar ones before. You also can't participate if you have certain health conditions like a significant risk of bleeding, a history of serious stomach bleeding, or specific heart, liver, or kidney problems. If you're allergic to any of the study medicines or similar types, or if your hives have a clear, single trigger (like a specific allergy to something), then you wouldn't be able to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Are you between 12 and 17 years old?
  2. Have you had chronic hives for at least 6 months?
  3. Have your hives not improved enough with regular allergy medicines?
  4. Do you currently have frequent itching and hives?
  5. Have you never taken this specific new medicine (LOU064) or similar ones?
  6. Do you have good overall health without major bleeding risks or liver/heart issues?
Answer every question to see your result.

What does participation involve?

If you join this study, it will be split into three main parts. First, for about 32 weeks, you'll be in the 'core period' where you'll visit the study site about 10 times. During this time, you'll receive either the study medicine (LOU064) or a dummy treatment (placebo) – you won't know which one. This is followed by an optional 'open-label extension' which could last from one year up to three years, with 3 to 15 visits depending on your hives. In this part, if your doctor agrees, you'll receive LOU064. Finally, there's an optional 'long-term follow-up' for three years, with one visit and up to four phone calls, where you won't receive any treatment but will be monitored for your health. The total time you could be involved in the study ranges from about 8 months to over 6 years.

Potential risks and benefits

Taking part in a study like this might offer potential benefits, such as receiving a new medicine that could help improve your chronic hives, possibly better than your current treatment. You will also be closely monitored by medical professionals, which means any health changes will be carefully checked. However, there are potential risks, including side effects from the study medicine; some of these might be unknown. You could also receive a placebo, meaning your hives might not improve during the initial part of the study. It's very important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (65)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • Kern Research
    Verified postcode
    Bakersfield, United States· Recruiting
  • Allergy and Asthma Medical Group and Research Center
    Verified postcode
    San Diego, United States· Recruiting
  • Pediatric Dermatology of Miami at the Pediatric CoE
    Verified postcode
    Miami, United States· Recruiting
  • Treasure Valley Medical Research
    Verified postcode
    Boise, United States· Active not recruiting
  • Endeavor Health
    Verified postcode
    Glenview, United States· Active not recruiting
  • Allergy and Asthma Specialist P S C
    Verified postcode
    Owensboro, United States· Recruiting
  • Toledo Institute of Clinical Research
    Verified postcode
    Toledo, United States· Recruiting
  • Allergy Asthma and Clinical Research
    Verified postcode
    Oklahoma City, United States· Recruiting
  • Allergy and Clinical Immunology Associates
    Verified postcode
    Pittsburgh, United States· Active not recruiting
  • RFSA Dermatology
    Verified postcode
    San Antonio, United States· Recruiting
  • Allergy Associates of Utah
    Verified postcode
    Sandy City, United States· Completed
  • Seattle Allergy and Asthma Rsch
    Verified postcode
    Seattle, United States· Withdrawn

Common questions

What are 'chronic spontaneous urticaria' (CSU)?

CSU refers to hives that appear regularly for at least six weeks, without a clear trigger, and can be very itchy.

What is a 'placebo'?

A placebo is a dummy treatment that looks just like the real medicine but contains no active drug. It helps researchers compare the real medicine's effects.

What does 'double-blind' mean?

It means that neither you nor your study doctor will know whether you are receiving the real medicine (LOU064) or the placebo.

How long will I be in the study overall?

The study could last from about 8 months up to over 6 years, depending on which optional parts you choose to join.

Can I leave the study at any time?

Yes, you are free to leave the study at any point, and doing so will not affect your future medical care.

How to find out more

Novartis Pharmaceuticals

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "24 Weeks Double-blind Randomized Placebo-controlled Trial to…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.